2 results
Approved WMOCompleted
To study the potential renoprotective effects of supplementation of alkaline phosphatase in hospitalized patients with AKI
Approved WMORecruiting
To compare the 120 mg once daily (QD) dose and 200 mg QD dose of MK*6482with respect to objective response rate (ORR) based on Response Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR).